Literature DB >> 24097336

U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.

A Tefferi1, C M Finke1, T L Lasho1, E A Wassie1, R Knudson2, R P Ketterling2, C A Hanson3, A Pardanani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24097336     DOI： 10.1038/leu.2013.286

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients.

Authors:  T L Lasho; C M Finke; C A Hanson; T Jimma; R A Knudson; R P Ketterling; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

Review 2.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

3.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

4.  Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

Authors:  M M Patnaik; E Padron; R R LaBorde; T L Lasho; C M Finke; C A Hanson; J M Hodnefield; R A Knudson; R P Ketterling; A Al-kali; A Pardanani; N A Ali; R S Komrokji; R S Komroji; A Tefferi
Journal:  Leukemia       Date:  2013-03-27       Impact factor: 11.528

5.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

6.  SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.

Authors:  Terra L Lasho; Thitina Jimma; Christy M Finke; Mrinal Patnaik; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

7.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.

Authors:  Bartlomiej Przychodzen; Andres Jerez; Kathryn Guinta; Mikkael A Sekeres; Richard Padgett; Jaroslaw P Maciejewski; Hideki Makishima
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

8.  Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.

Authors:  Shang-Ju Wu; Jih-Luh Tang; Chien-Ting Lin; Yuan-Yeh Kuo; Li-Yu Li; Mei-Hsuan Tseng; Chi-Fei Huang; Yen-Jun Lai; Fen-Yu Lee; Ming-Chih Liu; Chia-Wen Liu; Hsin-An Hou; Chien-Yuan Chen; Wen-Chien Chou; Ming Yao; Shang-Yi Huang; Bor-Sheng Ko; Woei Tsay; Hwei-Fang Tien
Journal:  Am J Hematol       Date:  2013-09-03       Impact factor: 10.047

9.  Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.

Authors:  Timothy A Graubert; Dong Shen; Li Ding; Theresa Okeyo-Owuor; Cara L Lunn; Jin Shao; Kilannin Krysiak; Christopher C Harris; Daniel C Koboldt; David E Larson; Michael D McLellan; David J Dooling; Rachel M Abbott; Robert S Fulton; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Marcus Grillot; Jack Baty; Sharon Heath; John L Frater; Talat Nasim; Daniel C Link; Michael H Tomasson; Peter Westervelt; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Matthew J Walter
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

10.  IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.

Authors:  A Tefferi; T Jimma; N H Sulai; T L Lasho; C M Finke; R A Knudson; R F McClure; A Pardanani
Journal:  Leukemia       Date:  2011-09-13       Impact factor: 11.528
View more
  27 in total

1.  Somatically acquired mutations in primary myelofibrosis: A case report and meta-analysis.

Authors:  Yongming Xia; Qingxiao Hong; Zhibin Gao; Shijun Wang; Shiwei Duan
Journal:  Exp Ther Med       Date:  2021-01-07       Impact factor: 2.447

2.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

Review 3.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

4.  Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Authors:  Ayalew Tefferi; Terra L Lasho; Paola Guglielmelli; Christy M Finke; Giada Rotunno; Yoseph Elala; Annalisa Pacilli; Curtis A Hanson; Alessandro Pancrazzi; Rhett P Ketterling; Carmela Mannarelli; Daniela Barraco; Tiziana Fanelli; Animesh Pardanani; Naseema Gangat; Alessandro M Vannucchi
Journal:  Blood Adv       Date:  2016-11-22

5.  Targeted deep sequencing in primary myelofibrosis.

Authors:  Ayalew Tefferi; Terra L Lasho; Christy M Finke; Yoseph Elala; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh Pardanani
Journal:  Blood Adv       Date:  2016-11-30

Review 6.  Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

Authors:  Alain Antoine Mina; Brady Stein
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 7.  New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

Authors:  Ami B Patel; Nadeem A Vellore; Michael W Deininger
Journal:  Clin Cancer Res       Date:  2016-03-01       Impact factor: 12.531

8.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

Authors:  A Tefferi; P Guglielmelli; T L Lasho; G Rotunno; C Finke; C Mannarelli; A A Belachew; A Pancrazzi; E A Wassie; R P Ketterling; C A Hanson; A Pardanani; A M Vannucchi
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

9.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

Review 10.  Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.

Authors:  Nisha R Singh
Journal:  Transl Pediatr       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.